In a report issued on October 8, Derek Archila from Stifel Nicolaus maintained a Buy rating on Argenx Se (NASDAQ: ARGX), with a price target of $139. The company’s shares closed yesterday at $69.13.
“We continue to like the stock ahead of the full ITP dataset expected at the Hematology (ASH) meeting in December, which we believe will address the bleeding rates controversy, and new data from ARGX-110’s Phase 1 study in AML, a program which has been gaining investor interest, which we don’t think is factored into Street models. We continue to view ARGX as the first-mover in the emerging anti-FcRn class which we believe could become a ~$20 billion category (FcRn deep dive report).”
According to TipRanks.com, Archila has currently no stars on a ranking scale of 0-5 stars, with an average return of -5.3% and a 30.1% success rate. Archila covers the Healthcare sector, focusing on stocks such as Rhythm Pharmaceuticals Inc, Pacira Pharmaceuticals, and Heron Therapeutics.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Argenx Se with a $144.40 average price target, implying a 108.9% upside from current levels. In a report issued on September 27, Nomura also maintained a Buy rating on the stock with a $161 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $103 and a one-year low of $22.21. Currently, Argenx Se has an average volume of 204.1K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
argenx SE is a clinical-stage biotechnology company, which engages in the research and development of human monoclonal antibodies for the treatment of cancer and oncological, autoimmune, and inflammatory diseases. Its products include ARGX-113 for severe autoimmune diseases and ARGX-110 for T-cell lymphoma and acute myeloid leukemia.